Healthcare Stocks
Last updated:
Healthcare stocks include businesses involved in medicines, biotechnology, medical devices, diagnostics, healthcare services, insurance and health technology. Demand can be supported by essential medical needs, but company outcomes still depend on clinical evidence, reimbursement, regulation, product cycles and execution.
The list below helps investors compare these different businesses rather than treating healthcare as a single defensive category.
List of Healthcare Stocks
Which Healthcare Stocks are gaining or losing interest?
Based on INDmoney Data: Search interest and investment activity.
Top Healthcare Stocks by Search Interest
INDmoney Data - Aug 9, 2026 to Sep 9, 2026
Stock | Monthly Change |
|---|---|
 Sionna Therapeutics, Inc. | 4766.00% |
 Celularity | 1750.00% |
 Moderna | 2303.00% |
 Amylyx Pharmaceuticals Inc | 1980.00% |
 MDxHealth | 1273.00% |
Top Healthcare Stocks by Investment Interest
INDmoney Data - Aug 9, 2026 to Sep 9, 2026
Stock | Monthly Change |
|---|---|
Sionna Therapeutics, Inc. | 7359.99% |
Amylyx Pharmaceuticals Inc | 2280.00% |
 Ultragenyx Pharmaceutical | 1727.27% |
 Tenon Medical, Inc. | 1686.66% |
 Quoin Pharmaceuticals | 1277.77% |
Which Healthcare Stocks Gained or Fell the Most in the Last Month?
Based on 1 month return. Aug 9, 2026 to Sep 9, 2026
Top Monthly Gainers
Stock | Monthly Change |
|---|---|
 Lexaria Bioscience | 168.50% |
Moderna | 145.99% |
Celularity | 195.92% |
 Capricor Therapeutics | 129.83% |
 Inovio Pharmaceuticals | 114.07% |
Top Monthly Losers
Stock | Monthly Change |
|---|---|
Sionna Therapeutics, Inc. | -85.93% |
 Curis | -66.42% |
 Alumis Inc. | -59.78% |
 Daré Bioscience | -48.50% |
 TransCode Therapeutics | -47.98% |
What are Healthcare Stocks?
Healthcare stocks are shares of companies that develop treatments, manufacture medical products, deliver care, process health information or finance medical services. Drug developers can depend on a small number of products and research programmes. Device makers may build recurring sales from consumables and service.
Hospitals, clinics and managed-care companies operate with different reimbursement and cost structures. Because the sector combines product innovation with regulated service delivery, the path from revenue growth to profit varies widely.
How do Healthcare Companies Make Money?
Pharmaceutical and biotech companies sell approved medicines, sometimes sharing economics through licences or partnerships. Medical-device companies earn from equipment, implants, consumables and support. Diagnostics businesses charge for tests or instruments. Providers receive payments from patients, employers, insurers and public programmes, while managed-care companies collect premiums and pay medical claims.
The source of payment matters: pricing power can be limited by insurers, government programmes, hospital purchasing groups or competition from alternative treatments.
What Drives Healthcare Stock Performance?
Clinical trial results and regulatory decisions can dominate individual drug developers, while utilisation, reimbursement and labour costs matter more for care providers. Demographics, disease prevalence and medical innovation support long-term demand, but they do not remove company-specific risk. Patent expiry, safety issues, changes in treatment standards and payer negotiations can alter profit quickly.
For diversified healthcare companies, investors should identify which products or segments produce most of the earnings and whether new launches can replace mature revenue.
Should You Invest in Healthcare Stocks?
Healthcare stocks may suit investors seeking exposure to medical demand and healthcare innovation who can tolerate clinical, reimbursement and regulatory setbacks. They may be less suitable for investors who need predictable returns or do not want to monitor category-specific drivers.
Before investing, compare:
- For medicine developers, review the approved portfolio, patent life, clinical pipeline, trial design, cash runway and concentration.
- For devices, study procedure volumes, installed base, consumables, innovation cycles and margins.
- For providers and insurers, focus on membership or patient volume, reimbursement, medical-cost trends, operating efficiency and regulatory exposure.
- Across the sector, free cash flow, research productivity, acquisition discipline and return on invested capital help show whether growth creates lasting value rather than only higher reported revenue.
Frequently Asked Questions (FAQs) about Healthcare Stocks:
The sector can include pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare providers, managed care, distributors and health technology companies.
Healthcare demand can be less sensitive to the economy because many treatments are necessary. However, drug approvals, reimbursement changes, patent losses and company-specific execution can still make individual stocks highly volatile.
Reimbursement risk is the possibility that insurers or public programmes will not cover a product or service at the expected price. Strong clinical results do not always guarantee favourable payment terms.
They can offer exposure to medical demand and healthcare innovation, but returns depend on company quality, entry valuation and clinical, reimbursement and regulatory setbacks.
For medicine developers, review the approved portfolio, patent life, clinical pipeline, trial design, cash runway and concentration. For devices, study procedure volumes, installed base, consumables, innovation cycles and margins.
Individual stocks give you control over company selection and valuation but add company-specific risk. A related ETF can spread exposure across several holdings. Compare the ETF's holdings, concentration, expense ratio and liquidity before deciding.
Clinical failure, safety issues, regulation, patent expiry, pricing pressure, reimbursement changes, litigation and acquisition risk are common. The importance of each risk depends on the subsector.